Delivery Order SPE2DB22D7065-SPE2DB25FH0NR

Award Date 10/23/24
Potential Completion Date 10/24/24
Potential Value $3.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of GARDASIL 9 syringes (0.5 mL) to the Defense Logistics Agency (DLA). The $5,773.01 firm fixed-price contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of October 11, 2024 and was awarded on October 10, 2024. This is a delivery order contract without any set-aside requirements, indicating open competition. AmerisourceBergen holds...
This federal contract award is for the delivery of GARDASIL 9 SYRINGE 0.5ML to the Defense Logistics Agency (DLA). The $11,327.08 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a completion date of June 26, 2024 and was not designated with a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, is for the supply of GARDASIL 9 syringes (0.5 mL) to the Defense Logistics Agency (DLA) Troop Support Medical. The $10,321.87 firm fixed-price delivery order has an ultimate completion date of October 9, 2024. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a range of medical...
This federal contract award is for the delivery of GARDASIL 9 syringes (0.5 mL) to the Defense Logistics Agency (DLA). The contract, valued at $8,760.13, was awarded to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Firm Fixed Price Delivery Order with a completion date of September 26, 2023. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with...
This federal contract award is for the delivery of GARDASIL 9 syringes (0.5 mL) to the Defense Logistics Agency (DLA), a defense agency of the U.S. government. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, and has a ceiling value of $6,794.48. The contract is a Delivery Order with a Firm Fixed Price pricing type, and the ultimate completion date is September 9, 2024. The contract was not set aside for any specific business type. AmerisourceBergen...
This federal contract award is for the delivery of GARDASIL 9 vaccine syringes to the Defense Logistics Agency (DLA), a defense agency. The $18,984.87 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract has an ultimate completion date of September 17, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 between AmerisourceBergen and the DLA Troop Support Medical, which...
This federal contract award is for the delivery of GARDASIL 9 syringes (0.5 mL) to the Defense Logistics Agency (DLA). The $2,951.03 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a completion date of February 25, 2025 and was awarded on February 24, 2025. It is not designated as a set-aside contract. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) valued...
This federal contract award is for the delivery of GARDASIL 9 syringes (0.5 mL) to the Defense Logistics Agency (DLA). The firm fixed-price contract, valued at $32,172.64, was awarded to the prime contractor AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of November 20, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support...
This federal contract award is for the delivery of GARDASIL 9 syringes (0.5 ml) to the Defense Logistics Agency (DLA). The contract was awarded to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, in the amount of $14,263.98. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of October 18, 2024. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC)...
This federal contract award is for the delivery of GARDASIL 9 syringes (0.5 mL) to the Defense Logistics Agency (DLA). The contract, valued at $4,563.97, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Firm Fixed Price Delivery Order with a period of performance through March 11, 2025. This award is not associated with a set-aside program. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC)...
  • SPE2DB22D7065
    Indefinite Delivery Contract
  • SPE2DB22D7065-SPE2DB25FH0NR
    Delivery Order

This federal contract award is for the delivery of GARDASIL 9 syringes (0.5 ml) to the Defense Logistics Agency (DLA). The $3,233.56 firm-fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on October 23, 2024 with an ultimate completion date of October 24, 2024. This contract is a child of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen's extensive federal contract awards demonstrate its critical role in supplying essential medical commodities to various government agencies, particularly the DLA, to meet the healthcare needs of military personnel, veterans, and other federal beneficiaries.

Generated 1/22/25, 9:15 AM